ORSERDU

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
ORSERDU
Generic name
ELACESTRANT
Manufacturer
Stemline Therapeutics, Inc.
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
aa66ae5c-2bd2-4444-8178-b55651e054ef
SPL ID
040abaf0-7a15-11f1-b55a-0800200c9a66
Version
9
Effective date
2026-06-24
Source export date
2026-11-13
Source partition
12
Source file
https://download.open.fda.gov/drug/label/drug-label-0012-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/df974ce21ba33b4471866e2af5412327fbd4bcd68d14b42d7cfb3aa15d163738/drug-label-0012-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 17:53:30
Harmonized routes table
Harmonized routes
ORAL

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Dyslipidemia : ORSERDU may cause hypercholesterolemia and hypertriglyceridemia. Monitor lipid profile prior to starting treatment and periodically thereafter. ( 5.1 ) Embryo-Fetal Toxicity : ORSERDU can cause fetal harm. Advise of the potential risk to a fetus and to use effective contraception. ( 5.2 , 8.1 , 8.3 ) 5.1 Dyslipidemia Hypercholesterolemia and hypertriglyceridemia occurred in patients taking ORSERDU at an incidence of 30% and 27%, respectively. The incidence of Grade 3 and 4 hypercholesterolemia and hypertriglyceridemia were 0.9% and 2.2%, respectively [see Adverse Reactions ( 6.1 )] . Monitor lipid profile prior to starting and periodically while taking ORSERDU. 5.2 Embryo-Fetal Toxicity Based on findings in animals and its mechanism of action, ORSERDU can cause fetal harm when administered to a pregnant woman. Administration of elacestrant to pregnant rats resulted in adverse developmental outcomes, including embryo-fetal mortality and structural abnormalities, at maternal exposures below the recommended dose based on area under the curve (AUC). Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with ORSERDU and for 1 week after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ORSERDU and for 1 week after the last dose [see Use in Specific Populations ( 8.1 , 8.3 ) and Clinical Pharmacology ( 12.1 )] .

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 3 matching rows.

adverse reactions

6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Dyslipidemia [see Warnings and Precautions ( 5.1 )] The most common (>10%) adverse reactions, including laboratory abnormalities, of ORSERDU were musculoskeletal pain, nausea, increased cholesterol, increased AST, increased triglycerides, fatigue, decreased hemoglobin, vomiting, increased ALT, decreased sodium, increased creatinine, decreased appetite, diarrhea, headache, constipation, abdominal pain, hot flush, and dyspepsia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Stemline Therapeutics, Inc. at 1-877-332-7961 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of ORSERDU was evaluated in 467 patients with ER+/HER2- advanced breast cancer following CDK4/6 inhibitor therapy in EMERALD, a randomized, open-label, multicenter study [see Clinical Studies ( 14 )] . Patients received ORSERDU 345 mg orally once daily (n=237) or standard of care (SOC) consisting of fulvestrant or an aromatase inhibitor (n=230). Among patients who received ORSERDU, 22% were exposed for 6 months or longer and 9% were exposed for greater than one year. Serious adverse reactions occurred in 12% of patients who received ORSERDU. Serious adverse reactions in >1% of patients who received ORSERDU were musculoskeletal pain (1.7%) and nausea (1.3%). Fatal adverse reactions occurred in 1.7% of patients who received ORSERDU, including cardiac arrest, septic shock, diverticulitis, and unknown cause (one patient each). Permanent discontinuation of ORSERDU due to an adverse reaction occurred in 6% of patients. Adverse reactions which resulted in permanent discontinuation of ORSERDU in >1% of patients were musculoskeletal pain (1.7%) and nausea (1.3%). Dosage interruptions of ORSERDU due to an adverse reaction occurred in 15% of patients. Adverse reactions which resulted in dosage interruption of ORSERDU in >1% of patients were nausea (3.4%), musculoskeletal pain (1.7%), and increased ALT (1.3%). Dosage reductions of ORSERDU due to an adverse reaction occurred in 3% of patients. Adverse reactions which required dosage reductions of ORSERDU in >1% of patients were nausea (1.7%). The most common (≥10%) adverse reactions, including laboratory abnormalities, of ORSERDU were musculoskeletal pain, nausea, increased cholesterol, increased AST, increased triglycerides, fatigue, decreased hemoglobin, vomiting, increased ALT, decreased sodium, increased creatinine, decreased appetite, diarrhea, headache, constipation, abdominal pain, hot flush, and dyspepsia. Table 3 summarizes the adverse reactions in EMERALD. Table 3: Adverse Reactions (>10%) in Patients with ER-positive, HER2-negative, Advanced or Metastatic Breast Cancer Who Received ORSERDU in EMERALD a a Adverse reactions were graded using NCI CTCAE version 5.0. b Includes other related terms c Only includes Grade 3 adverse reactions. Adverse Reaction ORSERDU (n=237) Fulvestrant or an Aromatase Inhibitor (n=230) All Grades (%) Grade 3 or 4 c (%) All Grades (%) Grade 3 or 4 c (%) Musculoskeletal and connective tissue disorders Musculoskeletal pain b 41 7 39 1 Gastrointestinal disorders Nausea 35 2.5 19 0.9 Vomiting b 19 0.8 9 0 Diarrhea 13 0 10 1 Constipation 12 0 6 0 Abdominal pain b 11 1 10 0.9 Dyspepsia 10 0 2.6 0 General disorders Fatigue b 26 2 27 1 Metabolism and nutrition disorders Decreased appetite 15 0.8 10 0.4 Nervous system Headache 12 2 12 0 Vascular disorders Hot flush 11 0 8 0 Clinically relevant adverse reactions in < 10% of patients who received ORSERDU included rash, insomnia, dyspnea, cough, dizziness, stomatitis and gastroesophageal reflux disease. Table 4 summarizes the laboratory abnormalities in EMERALD. Table 4: Select Laboratory Abnormalities (>10%) That Worsened from Baseline in Patients with ER-positive, HER2-negative, Advanced or Metastatic Breast Cancer Who Received ORSERDU in EMERALD a a The denominator used to calculate the rate varied from 29 to 236 for ORSERDU and from 37 to 225 for fulvestrant or an aromatase inhibitor based on the number of patients with a baseline value and at least one post-treatment value. Laboratory Abnormality ORSERDU a Fulvestrant or an Aromatase Inhibitor a All Grades (%) Grade 3 or 4 (%) All Grades (%) Grade 3 or 4 (%) Chemistry Cholesterol increased 30 1 17 0 Aspartate aminotransferase increased 29 0 34 1 Triglycerides increased 27 2 15 1 Alanine aminotransferase increased 17 0 24 1 Sodium decreased 16 1 15 0 Creatinine increased 16 0 6 0 Hematology Hemoglobin decreased 26 1 20 2

adverse reactions table

<table width="700" styleCode="Noautorules"><col width="32%" align="center" valign="middle"/><col width="17%" align="center" valign="middle"/><col width="17%" align="center" valign="middle"/><col width="17%" align="center" valign="middle"/><col width="17%" align="center" valign="middle"/><tfoot><tr><td align="left" colspan="5"><sup>a</sup>Adverse reactions were graded using NCI CTCAE version 5.0.</td></tr><tr><td align="left" colspan="5"><sup>b</sup>Includes other related terms</td></tr><tr><td align="left" colspan="5"><sup>c</sup>Only includes Grade 3 adverse reactions.</td></tr></tfoot><tbody><tr valign="middle"><td styleCode="Toprule Botrule Lrule Rrule Bold" rowspan="2">Adverse Reaction</td><td styleCode="Toprule Botrule Lrule Rrule Bold" colspan="2">ORSERDU (n=237)</td><td styleCode="Toprule Botrule Lrule Rrule Bold" colspan="2">Fulvestrant or an Aromatase Inhibitor (n=230)</td></tr><tr valign="middle"><td styleCode="Toprule Botrule Lrule Rrule Bold">All Grades (%)</td><td styleCode="Toprule Botrule Lrule Rrule Bold">Grade 3 or 4 <sup>c</sup> (%)</td><td styleCode="Toprule Botrule Lrule Rrule Bold">All Grades (%)</td><td styleCode="Toprule Botrule Lrule Rrule Bold">Grade 3 or 4 <sup>c</sup> (%)</td></tr><tr valign="middle"><td styleCode="Toprule Botrule Lrule Rrule Bold" colspan="5" align="left">Musculoskeletal and connective tissue disorders</td></tr><tr valign="middle"><td styleCode="Toprule Botrule Lrule Rrule" align="left">Musculoskeletal pain<sup>b</sup></td><td styleCode="Toprule Botrule Lrule Rrule" align="center">41</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">7</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">39</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">1</td></tr><tr valign="middle"><td styleCode="Toprule Botrule Lrule Rrule Bold" colspan="5" align="left">Gastrointestinal disorders</td></tr><tr valign="middle"><td styleCode="Toprule Botrule Lrule Rrule" align="left">Nausea</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">35</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">2.5</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">19</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">0.9</td></tr><tr valign="middle"><td styleCode="Toprule Botrule Lrule Rrule" align="left">Vomiting<sup>b</sup></td><td styleCode="Toprule Botrule Lrule Rrule" align="center">19</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">0.8</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">9</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">0</td></tr><tr valign="middle"><td styleCode="Toprule Botrule Lrule Rrule" align="left">Diarrhea</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">13</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">0</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">10</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">1</td></tr><tr valign="middle"><td styleCode="Toprule Botrule Lrule Rrule" align="left">Constipation</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">12</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">0</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">6</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">0</td></tr><tr valign="middle"><td styleCode="Toprule Botrule Lrule Rrule" align="left">Abdominal pain<sup>b</sup></td><td styleCode="Toprule Botrule Lrule Rrule" align="center">11</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">1</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">10</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">0.9</td></tr><tr valign="middle"><td styleCode="Toprule Botrule Lrule Rrule" align="left">Dyspepsia</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">10</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">0</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">2.6</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">0</td></tr><tr valign="middle"><td styleCode="Toprule Botrule Lrule Rrule Bold" colspan="5" align="left">General disorders</td></tr><tr valign="middle"><td styleCode="Toprule Botrule Lrule Rrule" align="left">Fatigue<sup>b</sup></td><td styleCode="Toprule Botrule Lrule Rrule" align="center">26</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">2</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">27</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">1</td></tr><tr valign="middle"><td styleCode="Toprule Botrule Lrule Rrule Bold" colspan="5" align="left">Metabolism and nutrition disorders</td></tr><tr valign="middle"><td styleCode="Toprule Botrule Lrule Rrule" align="left">Decreased appetite</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">15</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">0.8</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">10</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">0.4</td></tr><tr valign="middle"><td styleCode="Toprule Botrule Lrule Rrule Bold" colspan="5" align="left">Nervous system</td></tr><tr valign="middle"><td styleCode="Toprule Botrule Lrule Rrule" align="left">Headache</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">12</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">2</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">12</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">0</td></tr><tr valign="middle"><td styleCode="Toprule Botrule Lrule Rrule Bold" colspan="5" align="left">Vascular disorders</td></tr><tr valign="middle"><td styleCode="Toprule Botrule Lrule Rrule" align="left">Hot flush</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">11</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">0</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">8</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">0</td></tr></tbody></table>

adverse reactions table

<table width="700" styleCode="Noautorules"><col width="32%" align="center" valign="middle"/><col width="17%" align="center" valign="middle"/><col width="17%" align="center" valign="middle"/><col width="17%" align="center" valign="middle"/><col width="17%" align="center" valign="middle"/><tfoot><tr><td align="left" colspan="5"><sup>a</sup>The denominator used to calculate the rate varied from 29 to 236 for ORSERDU and from 37 to 225 for fulvestrant or an aromatase inhibitor based on the number of patients with a baseline value and at least one post-treatment value.</td></tr></tfoot><tbody><tr valign="top"><td align="left" styleCode="Toprule Botrule Lrule Rrule Bold" rowspan="2">Laboratory Abnormality</td><td styleCode="Toprule Botrule Lrule Rrule Bold" colspan="2">ORSERDU<sup>a</sup></td><td styleCode="Toprule Botrule Lrule Rrule Bold" colspan="2">Fulvestrant or an Aromatase Inhibitor<sup>a</sup></td></tr><tr valign="middle"><td styleCode="Toprule Botrule Lrule Rrule Bold">All Grades (%)</td><td styleCode="Toprule Botrule Lrule Rrule Bold">Grade 3 or 4 (%)</td><td styleCode="Toprule Botrule Lrule Rrule Bold">All Grades (%)</td><td styleCode="Toprule Botrule Lrule Rrule Bold">Grade 3 or 4 (%)</td></tr><tr valign="middle"><td styleCode="Toprule Botrule Lrule Rrule Bold" colspan="5" align="left">Chemistry</td></tr><tr valign="middle"><td styleCode="Toprule Botrule Lrule Rrule" align="left"> Cholesterol increased</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">30</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">1</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">17</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">0</td></tr><tr valign="middle"><td styleCode="Toprule Botrule Lrule Rrule" align="left"> Aspartate aminotransferase increased</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">29</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">0</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">34</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">1</td></tr><tr valign="middle"><td styleCode="Toprule Botrule Lrule Rrule" align="left"> Triglycerides increased</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">27</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">2</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">15</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">1</td></tr><tr valign="middle"><td styleCode="Toprule Botrule Lrule Rrule" align="left"> Alanine aminotransferase increased</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">17</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">0</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">24</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">1</td></tr><tr valign="middle"><td styleCode="Toprule Botrule Lrule Rrule" align="left"> Sodium decreased</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">16</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">1</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">15</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">0</td></tr><tr valign="middle"><td styleCode="Toprule Botrule Lrule Rrule" align="left"> Creatinine increased</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">16</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">0</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">6</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">0</td></tr><tr valign="middle"><td styleCode="Toprule Botrule Lrule Rrule Bold" colspan="5" align="left">Hematology</td></tr><tr valign="middle"><td styleCode="Toprule Botrule Lrule Rrule" align="left"> Hemoglobin decreased</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">26</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">1</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">20</td><td styleCode="Toprule Botrule Lrule Rrule" align="center">2</td></tr></tbody></table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.